DXCM Share Price

Open 81.60 Change Price %
High 82.26 1 Day -1.38 -1.69
Low 79.63 1 Week -4.92 -5.78
Close 80.21 1 Month 16.47 25.84
Volume 1224169 1 Year 7.73 10.67
52 Week High 96.38
52 Week Low 47.92
DXCM Important Levels
Resistance 2 82.65
Resistance 1 81.64
Pivot 80.70
Support 1 78.78
Support 2 77.77
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

DexCom, Inc. (NASDAQ: DXCM)

DXCM Technical Analysis 4
As on 20th Jan 2017 DXCM Share Price closed @ 80.21 and we RECOMMEND Buy for LONG-TERM with Stoploss of 74.07 & Strong Buy for SHORT-TERM with Stoploss of 66.98 we also expect STOCK to react on Following IMPORTANT LEVELS.
DXCM Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
DXCM Other Details
Segment EQ
Market Capital 902109952.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website http://www.dexcom.com
DXCM Address
DXCM
6340 Sequence Drive
San Diego, CA 92121
United States
Phone: 858-200-0200
Interactive Technical Analysis Chart DexCom, Inc. ( DXCM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on DexCom, Inc.
DXCM Business Profile
DexCom, Inc. (DexCom) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company had received approval from the United States Food and Drug Administration (FDA) for its third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use. The SEVEN PLUS is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices. The enabling technologies for the Company�s sensors include biomaterials, membrane systems, electrochemistry and low power microelectronics.